Boehringer Ingelheim and Eli Lilly and Company announced Tuesday, Sept. 15, that the FDA has granted a a Fast Track designation for the development of empagliflozin to improve patient outcomes following an acute myocardial infarction (ACI). The designation covers both patients with and without diabetes.
Empagliflozin, sold under the name Jardiance, is used to lower blood sugar in patients with type 2 diabetes. It is also prescribed to help reduce the risk of cardiovascular death in patients with type 2 diabetes and known cardiovascular disease.
“Ischemic heart disease (IHD) is the leading cause of death and disability in the U.S.,” Mohamed Eid, MD, MPH, MHA, vice president of clinical development and medical affairs for Boehringer Ingelheim’s cardio-metabolism and respiratory medicine division, said in a statement. “Myocardial infarction, or heart attack, is the deadliest acute manifestation of IHD, and treatment options are urgently needed to help improve outcomes.”